Company
Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Cytovia Therapeutics

Main focus: Next-generation iPSC-derived cell therapies

Company stage: Pre-clinical

Diseases (gene editing): Solid tumours, Multiple myeloma

Genome editing tool: TALEN, CRISPR

Funding stage: Private

Location: Aventura, Florida and New York, USA

Website: https://www.cytoviatx.com/

Pipeline: https://www.cytoviatx.com/our-products

Gene editing partnerships: Cellectis

Cytovia Therapeutics is a privately-held biotech company focused on the development of iPSC-derived natural killer (NK)- and CAR-NK cell therapies. The company uses CRISPR as well as TALEN technology, which it has licensed from Cellectis, for genomic editing of its NK cell candidates.

Tags

HashtagCytovia Therapeutics

close
Search CRISPR Medicine